ERBB2 and interstitial lung disease: Among patients who received an anti-HER2 drug as first-line therapy for advanced MBC, the ILD incidence was 1.8% (n = 1) [25], 3.3% (n = 2) [24], and 8.7% (n = 2) [18] across the three studies reporting on patients receiving lapatinib-based therapy for 10.4 months (median), trastuzumab-based therapy for 11 months (median), or trastuzumab-based therapy for 12.4 months (median) combined with pertuzumab for 11.3 months (median) and radiotherapy, respectively.